Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group
View abstract on PubMed
Summary
This summary is machine-generated.Non-metastatic hormone-sensitive prostate cancer (nmHSPC) patients represent a unique group with unmet needs. Identifying high-risk nmHSPC patients requires better biomarkers for tailored treatment strategies.
Area Of Science
- Oncology
- Urology
Background
- Non-metastatic hormone-sensitive prostate cancer (nmHSPC) describes patients with prostate cancer (PC) who are treatment-naïve and show no signs of metastasis.
- This group is heterogeneous, but high-risk nmHSPC patients without prior hormonal therapy present a distinct clinical challenge.
Purpose Of The Study
- To critically review advancements in the diagnosis and treatment of nmHSPC.
- To highlight the unmet clinical needs and evolving landscape for this patient population.
Main Methods
- This study is a narrative review of current literature.
- It critically discusses diagnostic and therapeutic advances in the nmHSPC setting.
Main Results
- nmHSPC is identified as a 'grey zone' in prostate cancer management.
- Current therapeutic algorithms are being redefined by new clinical trials, but broad treatment escalation may not be optimal.
- There is an urgent need for biomarkers, including molecular ones, to stratify nmHSPC patients.
Conclusions
- Accurate patient stratification is crucial for effective nmHSPC management.
- Biomarker-driven clinical trials are essential to define prognostic and predictive roles in nmHSPC.
- Future strategies must focus on personalized approaches rather than uniform treatment escalation.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...